NUI
No nā nīnau e pili ana i kā mākou huahana a i ʻole ka papa inoa kumukūʻai, e ʻoluʻolu e waiho i kāu leka uila iā mākou a e hoʻopili mākou i loko o 24 mau hola.
NINAU ANOKūlana halihali
Hiki i ka wela maʻamau
Manaʻo i ke ʻano hoʻouna
Ma ka lewa Ma ka aina Ma ke kai
Kūlana mālama:
E mālama i kahi pōʻeleʻele, Inert ea, lumi wela
Ola ola
Ma kahi o 2 makahiki
Ka nui o ke kauoha liʻiliʻi:
1kg (kūkākūkā)
palapala hōʻoia:COA, wahi hehee, Hoʻololi kikoʻī [α]D20
E hoʻouna mākou i nā ʻikepili āu e makemake ai.Hiki iā ʻoe ke ʻike i ka ʻikepili ma mua ma ke ʻano he kuhikuhi.
No nā huahana maʻamau, hoʻouna mākou i ka ʻikepili hou ma hope o ka puka ʻana mai.
N2-Boc-L-lysine;
N-alpha-Acetyl-Nεn-Boc-L-lysine;
(2S)-6-amino-2-(tert-butoxycarbonylamino)hexanoicacid;
(2S)-6-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoicacid;
(S)-2-[(tert-Butyloxycarbonyl)amino]-6-aminohexanoicacid
Hoʻohana pinepine ʻia lākou no ka hoʻopili ʻana i ka pauka.Pili ia i nā koi o nā mea kūʻai aku.No ka mālama pono i ka hōʻea ʻana i kahi e hele ai.E hoʻopaʻa mākou i nā ʻōmole plastik me ka lipine plastik keʻokeʻo ma ka hakahaka o nā poʻi.
He paʻakikī ka paʻi waho.A he mea paʻakikī ke ʻoki a hōʻino.Hiki iā ia ke pale pono i kāu mau huahana.E hele mākou i ka lipine plastik i waho e hoʻoponopono i kēlā me kēia ʻāpana.A inā pono, e hoʻopaʻa ʻia mākou me nā kiʻi ʻoniʻoni ma waho.
ʻO 13734-28-6 Boc-Lys-OH, i ʻike ʻia ʻo N-alpha-tert-butoxycarbonyl-L-lysine, he reagent biochemical i hiki ke hoʻohana ʻia ma ke ʻano he hale kūkulu i nā noiʻi noiʻi ʻepekema ola.
ʻO ka mea kūikawā, 13734-28-6 Boc-Lys-OH ke komo i ka synthesis o nā peptides thymic e like me β4, βg, a me β6 mau ʻāpana.Hoʻonui ia i ka hiki ke hoʻokumu ʻana i ka E-rosette a hoʻokani i kahi hana i nā kumu hoʻohālike lupus nephritis.Hoʻohui ʻia, hoʻohana ʻia ʻo Boc-Lys-OH i ka synthesis o Boc-Lyz-OCH3 a lawelawe ʻo ia ma ke ʻano he reagent hana no ka peptide-based thrombin inhibitors.
13734-28-6 ʻO Boc-Lys-OH kekahi o nā mea waena o Tirzepatide.
ʻO Tirzepatide kahi mea hoʻokipa glucagon-like peptide-1 (GLP-1) a me ka glucose-dependent insulinotropic polypeptide (GIP) dual receptor agonist, lawelawe ʻia i hoʻokahi pule. ʻāpana o ke kino o ke kanaka, a hiki i ka mea mua ke hoʻopaʻa i ka mea hoʻokipa ma nā ʻāpana pancreatic islet a hoʻoulu i ka huna ʻana o ka insulin, no laila e hoʻoulu ai i nā hopena hoʻohaʻahaʻa glucose, a hoʻopaneʻe hoʻi ia i ka hoʻokaʻawale ʻana o ka ʻōpū a hoʻopaʻa i ka ʻai, no laila ke kāohi nei i ke kaumaha o ke kino;ʻoiai ʻo ka mea hope ka hana o ke kāohi ʻana i ka ʻakika ʻōpū, hoʻoulu i ka hoʻokuʻu ʻana o ka insulin, a ke kāohi nei i ka motility ʻōpū a me ka hoʻokuʻu ʻana, hiki ke hoʻohui iā GLP-1.Hiki i ka mea mua ke hoʻopaʻa i nā mea i loaʻa i ka pancreatic islet cell a hoʻoulu i ka huna ʻana o ka insulin, no laila e hana ana i kahi hopena hypoglycemic, a me ka hoʻopaneʻe ʻana i ka ʻōpū o ka ʻōpū a me ka hoʻopau ʻana i ka makemake, pēlā e hoʻomalu ai i ke kaumaha o ke kino;ʻoiai ka mea hope i nā hana o ke kāohi ʻana i ka waikawa gastric a me ka huna ʻana o ka pepsin, hoʻoulu i ka hoʻokuʻu ʻana o ka insulin, ke kāohi ʻana i ka peristalsis o ka ʻōpū a me ka hoʻokuʻu ʻana, a hiki ke hoʻohui i ke kuleana o ka agonist GLP-1.
Lys(Fmoc).HCl | Cbz-L-Lys(Fmoc)-OH | Boc-Lys(Cbz).DCHA |
Boc-Lys(tfa)-OH | Boc-Lys(Cbz)-Ol | Boc-Lys(AC)-OH |
Boc-L-Lys(Cbz)-OH | Boc-L-Lys(Boc)-OSu | Boc-L-Lys(Boc)-OH·DCHA |
Boc-Lys(Boc)-OH | Boc-D-Lys(Boc)-OH | Boc-L-Lys(Fmoc)-OH |
Fmoc-L-Lys(tfa)-OH | Fmoc-D-Lys(Boc)-OH | Fmoc-L-Lys(Boc)-OH |
Cbz-Lys(Boc)-ome-OH | Cbz-Lys(Boc)-Otbu-OH | Cbz-L-Lys(BOC)-OH |
1. ʻO kā mākou mau hale hana ISO 9001, ISO 14001 a me ISO 45001 i hōʻoia ʻia.
2. ʻOihana hui lawelawe pūnaewele, e pane ʻia kēlā me kēia leka uila i loko o 24 mau hola.
3. Loaʻa iā mākou kahi hui ikaika e hāʻawi i kā mākou mea kūʻai aku i ka lawelawe naʻau holoʻokoʻa i nā manawa a pau.
4. Ke koi nei mākou e hele mua kā mākou mea kūʻai a makemake kā mākou poʻe limahana i ka hauʻoli.
5. E noʻonoʻo mua i ka maikaʻi.